Antibodies

15 May 2018 FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
14 May 2018 CStone announces first patient dosing with anti-PD-1 antibody CS1003 in Phase I study in Australia
11 May 2018 AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
10 May 2018 NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate
10 May 2018 Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
10 May 2018 Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab,” Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
09 May 2018 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma
07 May 2018 OSE Immunotherapeutics Presents New Data on OSE-127 at the American Association of Immunologists (AAI) Annual Meeting May 4-8 2018 in Austin, Texas
07 May 2018 FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
05 May 2018 Evolve Biologics™ Reaches Major Milestones in Phase III Trial for PlasmaCap™ IG (Intravenous Immunoglobulin), Including Dosing of First Pediatric Patient
04 May 2018 CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia
03 May 2018 European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)
03 May 2018 Merck Provides Update on KEYNOTE-407 Trial
03 May 2018 Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
03 May 2018 New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors
02 May 2018 NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers
02 May 2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
01 May 2018 AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
01 May 2018 Aptevo Therapeutics Announces IND Submission for APVO436
30 Apr 2018 Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
30 Apr 2018 FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC
30 Apr 2018 Ablynx completes patient recruitment in the phase IIb RESPIRE study of its inhaled anti-RSV nanobody ALX-0171
30 Apr 2018 FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
28 Apr 2018 Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
28 Apr 2018 Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top